Stock News & Analysis

Can Peloton be the year's biggest turnaround story?

There's a reason many retirees may be disappointed in their benefits this year.

Maze Therapeutics' Senior Vice President of Finance sold shares towards the end of January 2026, all while the company's stock had one of the best first-year performances of a biopharmaceutical company.

Workers with median earnings can build sizable portfolios that pay a substantial amount of passive income.

Costco and Walmart are two of the world's largest retailers.

Wall Street's foundational financial institution is rife with red flags, and the stock market could pay the price.

Beam Therapeutics specializes in gene-editing medicines, and recently, the company's Senior Vice President edited out thousands of shares from her portfolio.

Retirees' 2026 Social Security COLA might taste a little better after a recent government report.

These Vanguard funds won't necessarily keep you from losing money if the market crashes. But they can help cushion the blow.

In all three cases it started with a must-have product or service that's easy and affordable enough to buy over and over again.

AMD has a foot in the door of the booming space economy.

Sandisk stock increased 16x in the past year as demand for artificial intelligence infrastructure led to a severe supply shortage in memory chips and storage devices.

Billionaires are buying this maker of critical mapping and positioning software at a discount.

The CEO of this leading medical diagnostic company sold shares throughout multiple days in January. But the manner in which the shares were sold shouldn't concern investors.

Leisure stocks can provide good returns, if you can ride out the waves during economic downturns.

This top executive at Harmony Biosciences previous sold all of his direct shares in the company in early January 2026. But towards the end of the month, some options and restricted stock units vested, and everything changed.

These two stock-split stocks still have a long runway ahead.

The Chief Scientific Officer of Scholar Rock Holding Corp has made multiple filings regarding disposals in January 2026, but this should not alarm investors.

Beyond Meat was a market darling when it first went public, but you'll want to tread cautiously if you are looking to buy it today.

A large biotech fund that's an insider at Cogent Biosciences recently sold millions of shares amid the company's best annual performance ever in 2025.